Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Arch Dermatol Res ; 316(7): 350, 2024 Jun 08.
Article in English | MEDLINE | ID: mdl-38850408

ABSTRACT

Loss and absence of melanocytes due to a number of factors is responsible for vitiligo; known to be the commonest disorder of pigmentation. The aim of the current work was to compare the efficacy and safety of excimer light with topical tacrolimus ointment 0.1% versus excimer light with topical bimatoprost gel 0.01% in treatment of facial vitiligo. The study was carried out on 48 patients presented with facial vitiligo. The patients were divided randomly using sealed envelope method into two groups (24 patients each). Group 1 were treated with excimer light plus topical tacrolimus ointment 0.1% and group 2 treated with excimer light plus topical bimatoprost gel 0.01%. Clinical improvement based on the quartile grading scale at the end of treatment did not show any statistically significant difference between groups. The majority of subjects in both groups experienced good to excellent improvement. Only 20.9% of patients in group 1 and 33.3% of subjects in group 2 achieved less than 50% repigmentation (p = 0.889). Our study demonstrated that 0.01% topical bimatoprost gel in combination with excimer light is considered safe and effective as treatment of nonsegmental facial vitiligo with comparable results to 0.1% tacrolimus.


Subject(s)
Bimatoprost , Tacrolimus , Vitiligo , Humans , Vitiligo/drug therapy , Vitiligo/therapy , Vitiligo/diagnosis , Tacrolimus/administration & dosage , Bimatoprost/administration & dosage , Female , Male , Adult , Treatment Outcome , Young Adult , Adolescent , Middle Aged , Lasers, Excimer/therapeutic use , Administration, Topical , Skin Pigmentation/drug effects , Skin Pigmentation/radiation effects , Face , Administration, Cutaneous , Child , Combined Modality Therapy/methods , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use
2.
Sci Rep ; 14(1): 288, 2024 01 02.
Article in English | MEDLINE | ID: mdl-38167543

ABSTRACT

Molluscum contagiosum (MC) is a skin and mucous membrane infection caused by the molluscum virus (MCV). To evaluate safety and efficacy of intralesional injection of tuberculin purified protein derivative (PPD) antigen injection versus MMR (mumps, measles, rubella) antigen for the treatment of molluscum contagiosum (MC). A total of thirty clinically confirmed patients of molluscum were recruited for this trial. Patients who were divided into three groups (A, B and C). Each group consisted of (30) patients. Group (A) subjects received intralesional MMR injections, group (B) subjects received intralesional PPD injection and group (C) received intralesional saline injection. The results of the present study revealed complete clearance of the injected lesions in 12 patients (80%), partial response in 3 patients (20%) of group (A). In group (B), complete clearance of the treated warts was observed in 11 patients (73.3%) and partial response in 4 (26.7%) of patients. In group (C), the majority of patients 8 (53.3%) demonstrated no response while 7 (46.7%) patients showed only partial clearance. We established a good safety and efficacy profile for tuberculin PPD and MMR antigens in treatment of molluscum contagiosum.


Subject(s)
Measles-Mumps-Rubella Vaccine , Molluscum Contagiosum , Tuberculin , Humans , Injections, Intralesional , Measles-Mumps-Rubella Vaccine/therapeutic use , Molluscum Contagiosum/drug therapy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL